Trial Updates

VISIONARY-MS: pure gold nanocrystals for neurorepair and neuroprotection in MS 4:51
VISIONARY-MS: pure gold nanocrystals for neurorepair and neuroprotection in MS
Robert Glanzman • 1 Mar 2021
REPAIR-MS: 31P-MRS imaging to assess the effects of CNM-Au8 in MS 3:30
REPAIR-MS: 31P-MRS imaging to assess the effects of CNM-Au8 in MS
Robert Glanzman • 1 Mar 2021
Novel epilepsy treatment: minimally invasive stimulation 1:46
Novel epilepsy treatment: minimally invasive stimulation
Andreas Schulze-Bonhage • 29 Oct 2020
Long-term intermittent use of ubrogepant to treat acute migraines 5:26
Long-term intermittent use of ubrogepant to treat acute migraines
Jessica Ailani • 26 Oct 2020
Lessons to be learned from the laquinimod trial for MS 1:50
Lessons to be learned from the laquinimod trial for MS
Gavin Giovannoni • 19 Oct 2020
The future of Alzheimer’s disease: aducanumab 2:38
The future of Alzheimer’s disease: aducanumab
John Hardy • 20 Oct 2020
Developments in Parkinson’s disease research and PASADENA clinical trial update 3:21
Developments in Parkinson’s disease research and PASADENA clinical trial update
Tiago Outeiro • 18 Sep 2020
Beneficial effects of aerobic exercise in slowing Parkinson’s disease progression 4:09
Beneficial effects of aerobic exercise in slowing Parkinson’s disease progression
Terry Ellis • 14 Sep 2020
Appraisal of Huntington’s disease clinical trials 2:50
Appraisal of Huntington’s disease clinical trials
Joaquim Ferreira • 4 Sep 2020
The 4 Repeat Tauopathy Neuroimaging Initiative 2:00
The 4 Repeat Tauopathy Neuroimaging Initiative
Adam Boxer • 9 Sep 2020
The problems arising in ASO clinical trials and future preparations 3:38
The problems arising in ASO clinical trials and future preparations
Joaquim Ferreira • 4 Sep 2020
Opicapone shows better motor performance in Parkinson’s disease compared to entacapone 3:37
Opicapone shows better motor performance in Parkinson’s disease compared to entacapone
Joaquim Ferreira • 4 Sep 2020
ASO tominersen for Huntington’s disease in Phase III trials 2:20
ASO tominersen for Huntington’s disease in Phase III trials
Edward Wild • 4 Sep 2020
Personalized medicine in Parkinson’s disease 2:26
Personalized medicine in Parkinson’s disease
Oscar Gershanik • 4 Sep 2020
CGRP monoclonal antibodies & migraine management during COVID-19 pandemic 20:54
CGRP monoclonal antibodies & migraine management during COVID-19 pandemic
Stewart Tepper • 24 May 2020
Benefit of migraine prevention with erenumab 19:11
Benefit of migraine prevention with erenumab
Stewart Tepper • 24 May 2020
The content of VJNeurology is intended for healthcare professionals